中文字幕无码不卡在线,台湾佬自拍偷区亚洲综合,国产凹凸在线一区二区,小荡货奶真大水多好紧视频

您好,歡迎光臨欣博盛生物科技商城!
服務(wù)熱線(xiàn):400 680 0892
BioXcell
品牌名:

BioXcell

國家: 美國
網(wǎng)址: http://www.bxcell.com

BioXCell的中和/阻斷抗體受到國內外研究者的普遍熱愛(ài)和青睞,在腫瘤、癌癥等方面的研究中廣受好評。BioXCell公司位于美國新罕布什爾州,具有25年以上單克隆抗體和重組蛋白的生產(chǎn)及定制經(jīng)驗,可提供高純度、低內毒素、無(wú)防腐劑、適用于體內臨床前研究的單克隆抗體。


欣博盛生物是Bioxcell一級代理商,Bioxcell國內唯一庫存中心。如需購買(mǎi)Bioxcell公司產(chǎn)品,請聯(lián)系我們。


BioXCell——助力體內臨床前研究高純度、低內毒素,無(wú)防腐劑,適用于體內臨床前研究
超過(guò)二十五年單克隆抗體和重組蛋白生產(chǎn)及定制經(jīng)驗
性?xún)r(jià)比高,可提供100mg甚至50g的大包裝
超過(guò)15000篇高質(zhì)量期刊文獻引用


腫瘤癌癥免疫治療應用?

抑制免疫檢查點(diǎn)和其他免疫調節來(lái)治療惡性腫瘤是現在利用免疫系統殺死腫瘤細胞的有力途徑。BioXCell提供三種不同克隆號的anti?mouse PD-1抗體:RMP1-14、29F.1A12和J43。三種抗體都通過(guò)相同的機制發(fā)揮作用—它們結合PD-1,并在空間上阻斷PD-1與PD-1配體的結合,從而阻斷PD-1信號傳導。這三種克隆號的抗體都非常適合在小鼠體內模型中阻斷PD-1信號傳導,并有大量文獻支持這一應用。這些抗體之間的差異在于文獻報道中的其他應用、Isotype和來(lái)源。

通過(guò)用阻斷PD-L1和它的受體PD-1之間的相互作用的抗體治療,腫瘤生長(cháng)可以暫時(shí)被抑制。

抗PD-1聯(lián)合抗CTLA-4抗體介導的免疫治療對黑色素瘤、腎細胞癌和非小細胞肺癌具有顯著(zhù)療效。

通過(guò)靶向調節免疫反應的途徑,如RANK途徑,可以將“cold”腫瘤轉化為“hot”腫瘤。使用Bio X Cell’s Anti-mouse RANKL (clone IK22/5) antibody,研究人員證明了對RANK通路的抑制將“cold”乳腺腫瘤轉化為“hot”腫瘤,變?yōu)椤癶ot”的腫瘤可能受益于免疫療法。



腫瘤研究相關(guān)的抗體

抗體指標應用克隆號InVivoMabInVivoPlus同型對照稀釋液
Anti mouse PD-1(CD279)In vivo blocking of PD-1/PD-L signalingRMP1-14BE0146BP0146BE0089IP0070
In vivo blocking of PD-1/PD-L signaling
In vitro PD-1 neutralization
IHC-Fr/Immunofluorescence/WB/FC
29F.1A12BE0273BP0273BE0089IP0070
In vivo blocking of PD-1/PD-L signaling
In vitro PD-1 neutralization
WB
J43BE0033-2BP0033-2BE0091IP0065
Anti mouse PD-L1(B7-H1)In vivo PD-L1 blockade
IHC-Fr/Immunofluorescence/WB/FC
10F.9G2BE0101BP0101BE0090IP0065
Anti mouse CTLA-4 (CD152)In vivo CTLA-4 neutralization
WB
9D9BE0164BP0164BE0086IP0070
In vivo CTLA-4 neutralization
In vitro CTLA-4 neutralization
WB
9H10BE0131BP0131BE0087IP0070
In vivo CTLA-4 neutralization
In vitro CTLA-4 neutralization
WB/FC
UC10-4F10-11BE0032BP0032BE0091IP0065
Anti mouse CD4In vivo CD4+ T cell depletion
WB/FC
GK1.5BE0003-1BP0003-1BE0090IP0065
Anti mouse CD8αIn vivo CD8+ T cell depletion
Immunofluorescence/WB/FC
53-6.7BE0004-1BP0004-1BE0089IP0065
In vivo CD8+ T cell depletion
WB
2.43BE0061BP0061BE0090IP0070
In vivo CD8+ T cell depletion
WB
YTS 169.4BE0117BP0117BE0090IP0070
Anti mouse Ly6GIn vivo neutrophil depletion
In vivo MDSC depletion
IHC-P/IHC-Fr/IF/FC
1A8BE0075-1BP0075-1BE0089IP0065
Anti mouse Ly6G/Ly6C (Gr-1)In vivo depletion of Gr-1+ myeloid cells
IHC-P/IHC-Fr/FC
RB6-8C5BE0075BP0075BE0090IP0070
Anti mouse IFNγIn vivo IFN-γ neutralization
In vitro IFN-γ neutralization
ELISPOT/WB/FC
XMG1.2BE0055BP0055BE0088IPT080
Anti mouse IFNAR-1In vivo IFNAR-1 blockade
In vitro IFNAR-1 blockade
WB
MAR1-5A3BE0241BP0241BE0083IP0070

Anti-mouse/human/rat/monkey/hamster/

canine/bovine TGF-β

In vivo TGF-β neutralization
In vitro TGF-β neutralization
WB
1D11.16.8BE0057BP0057BE0083IP0070
Anti mouse CD28In vitro T cell stimulation/activation
In vivo CD28 blockade
37.51BE0015-1/BE0087IPT060
in vitro T cell stimulation/activationPV-1BE0015-5/BE0091IP0070
Anti mouse CD3εIn vitro T cell stimulation/activation
In vivo T cell depletion
Immunofluorescence/WB/FC
145-2C11BE0001-1BP0001-1BE0091IP0070
Anti-human CD3In vitro T cell stimulation/activation
In vivo T cell depletion in humanized mice
Ex vivo T cell inhibition for xenografts
FC
OKT-3BE0001-2/BE0085IP0070
Anti mouse CD40In vivo CD40 activation
In vitro B cell stimulation/activation
FGK4.5/ FGK45BE0016-2BP0016-2BE0089IP0070
Anti mouse CD154 (CD40L)In vivo blocking of CD40/CD40L signaling
In vitro blocking of CD40/CD40L signaling
WB
MR-1BE0017-1BP0017-1BE0091IP0070
Anti mouse CD25 (IL-2Rα)In vivo regulatory T cell depletion
FC
PC-61.5.3BE0012BP0012BE0088IP0070
Anti mouse IL-4In vivo IL-4 neutralization
In vitro IL-4 neutralization
In vivo IL-4 receptor stimulation (as a complex with IL-4)
FC/WB
11B11BE0045BP0045BE0088IP0070
Anti mouse NK1.1In vivo NK cell depletion
FC
PK136BE0036BP0036BE0085IP0070
Anti mouse CSF1R (CD115)In vivo macrophage depletion
In vitro CSF1R neutralization
In vivo monocyte depletion
FC/WB
AFS98BE0213BP0213BE0089IP0070
Anti mouse CD25?(IL-2Rα)In vivo?regulatory T cell depletion
FC
PC-61.5.3BE0012BP0012BE0088IP0070
anti-mouse OX40 (CD134)In vivo OX40 activation
In vitro OX40 activation
WB
OX-86BE0031BP0031BE0088IP0070


暢銷(xiāo)同型對照抗體

同型對照InVivoMabInVivoPlus

目錄號目錄號
Rat IgG2a Isotype control, FCBE0089BP0089
Rat IgG2b Isotype controlBE0090BP0090
Mouse IgG1 Isotype controlBE0083BP0083
Rat IgG1 Isotype controlBE0088BP0088
Mouse IgG2a Isotype controlBE0085BP0085
Mouse IgG2b Isotype controlBE0086BP0086
Polyclonal Armenian Hamster IgGBE0091BP0091



InVivoPlus? Vs InVivoMab?系列之間區別


InVivoMabInVivoPlus
純度> 95%> 95%
蛋白完整性√ (verified via SDS-PAGE)√ü(verified via SDS-PAGE)
內毒素濃度< 2EU/mg< 1EU/mg
不含疊氮化物和載體蛋白
是否適用于體內研究
是否提供大包裝
是否經(jīng)WB, FC或ELISA驗證
經(jīng)驗證蛋白聚集≤?5%
是否經(jīng)過(guò)鼠科病原體檢測
產(chǎn)品貨號BE-開(kāi)頭BP-開(kāi)頭


BioXCell的RecombiMAb系列抗體

BioXCell的RecombiMAb系列抗體是新開(kāi)發(fā)的重組單克隆抗體,具有與其傳統克隆號來(lái)源相同的抗原結合可變區,但IgG恒定區已從大鼠或倉鼠IgG變?yōu)樾∈蠡蛉薎gG。這意味著(zhù)對于小鼠模型或人源化小鼠模型的免疫原性降低。


RecombiMAb單克隆抗體

產(chǎn)品名稱(chēng)宿主亞型貨號同型對照稀釋液應用
Anti-Mouse PD-1 (CD279) (D265A)MouseIgG2a, ΚCP151CP150IP0070in vivo blocking of PD-1/PD-L signaling
Anti-Mouse CTLA-4 (CD152)MouseIgG1, ΚCP146BP0083IP0070In vivo CTLA-4 neutralization?
In vitro CTLA-4 neutralization?
WB
Human IgG4 (S228P) Isotype Control, Anti-Hen Egg LysozymeHumanIgG4, ΚCP147---
Human IgG4 S228P L235E P329G (SPLEPG) Isotype Control, Anti-Hen Egg LysozymeHumanIgG4CP148---
Human IgG1 (LALA-PG) Isotype Control, Anti-Hen Egg LysozymeHumanIgG1CP149---
Mouse IgG2a (D265A) Isotype Control, Anti-Hen Egg LysozymeMouseIgG2aCP150---

BioXCell的重組融合蛋白

融合蛋白即通過(guò)將細胞表面受體的結合域與抗體的Fc部分結合而形成,這樣可以使得配體分子不會(huì )結合到內源性受體,從而阻斷受體信號的傳導。蛋白純度大于95%,內毒素水平超低,不含防腐劑、穩定劑和載體蛋白等試劑,專(zhuān)為體內研究而開(kāi)發(fā)。

貨號產(chǎn)品名稱(chēng)貨號產(chǎn)品名稱(chēng)規格
BE0099InVivoMAb recombinant CTLA-4-lgBP0099InVivoPlus recombinant CTLA-4-Ig5mg,25mg,50mg,100mg
BE0098InVivoMAb recombinant Flt-3L-lgBE0148InVivoMAb recombinant Mouse Angiostatin-lg5mg,25mg,50mg,100mg
BE0149InVivoMAb recombinant Mouse Endostatin-lg--5mg,25mg,50mg,100mg


產(chǎn)品示例(圖片):

BioXCell——助力體內臨床前研究




更多詳情請聯(lián)系 BioXcell 中國金牌代理商欣博盛生物

全國服務(wù)熱線(xiàn): 4006-800-892? ? ? ?郵箱: market@neobioscience.com? ?

深圳: 0755-26755892? ? ? ?北京: 010-88594029? ? ? ? ?

上海: 021-34613729? ? ? ? ?廣州: 020-87615159

代理品牌網(wǎng)站: www.yeahgoo.com.cn? ?

自主品牌網(wǎng)站: www.neobioscience.net

糖型分析網(wǎng)站:www.glycan-analysis.com??

關(guān)注欣博盛公眾號
Copyright ?2021 - 2023 深圳欣博盛生物科技有限公司
  網(wǎng)站地圖
犀牛云提供企業(yè)云服務(wù)